DAVID ENLOE

Prior to Societal, he was President and CEO of Ajinomoto Bio-Pharma Services, a global, fully integrated CDMO; prior to that David was the Head of Lonza’s Viral Therapeutics Business Unit, which grew out of the acquisition of Vivante GMP Solutions, a gene therapy CDMO that he founded and where he was President and CEO. 

David also has approximately fifteen years of experience on the CDMO client side, having been the first employee and Senior Vice President of Operations of Introgen Therapeutics, Inc., one of the first gene therapy development companies in the world, where David oversaw the creation of the first commercial scale viral vector facility in the United States.

David received a Bachelor of Business Administration, Accounting from the University of Texas at Austin. He is a Certified Public Accountant and started his career in public accounting with Arthur Andersen & Co.